Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

被引：0
|
作者：
Van Cutsem, E. [1 ,2 ]
Amonkar, M. [3 ]
Fuchs, C. S. [4 ]
Alsina, M. [5 ,6 ]
Ozguroglu, M. [7 ]
Bang, Y-J. [8 ]
Chung, H. C. [9 ]
Muro, K. [10 ]
Goekkurt, E. [11 ]
Benson, A. [12 ]
Sun, W. [13 ]
Wainberg, Z. A. [14 ]
Norquist, J. [3 ]
Chen, X. [3 ]
Shih, C-S. [3 ]
Shitara, K. [15 ]
机构：
[1] Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven, Belgium
[3] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[4] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[5] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[6] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain
[7] Istanbul Univ Cerrahpasa, Clin Trial Unit, Cerrahpasa Sch Med, Internal Med,Med Oncol, Istanbul, Turkey
[8] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea
[9] Yonsei Univ, Med Oncol, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[10] Aichi Canc Ctr Hosp, Clin Oncol, Nagoya, Aichi, Japan
[11] Univ Canc Ctr Hamburg, HOPE, North German Trial Ctr Innovat Oncol NIO, Hamburg, Germany
[12] Northwestern Med Fac Fdn, Hematol Oncol, Chicago, IL USA
[13] Univ Kansas, Internal Med, Med Oncol, Westwood, KS USA
[14] Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol & Oncol, Los Angeles, CA 90095 USA
[15] Natl Canc Ctr Hosp, Gastrointestinal Oncol, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
791P
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [1] Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
    Van Cutsem, Eric
    Amonkar, Mayur
    Fuchs, Charles S.
    Alsina, Maria
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    Benson, Al B., III
    Sun, Weijing
    Wainberg, Zev A.
    Norquist, Josephine M.
    Chen, Xinqun
    Shih, Chie-Schin
    Shitara, Kohei
    GASTRIC CANCER, 2021, 24 (06) : 1330 - 1340
  • [2] Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
    Eric Van Cutsem
    Mayur Amonkar
    Charles S. Fuchs
    Maria Alsina
    Mustafa Özgüroğlu
    Yung-Jue Bang
    Hyun Cheol Chung
    Kei Muro
    Eray Goekkurt
    Al B. Benson
    Weijing Sun
    Zev A. Wainberg
    Josephine M. Norquist
    Xinqun Chen
    Chie-Schin Shih
    Kohei Shitara
    Gastric Cancer, 2021, 24 : 1330 - 1340
  • [3] Correction to: Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
    Eric Van Cutsem
    Mayur Amonkar
    Charles S. Fuchs
    Maria Alsina
    Mustafa Özgüroğlu
    Yung-Jue Bang
    Hyun Cheol Chung
    Kei Muro
    Eray Goekkurt
    Al B. Benson
    Weijing Sun
    Zev A. Wainberg
    Josephine M. Norquist
    Xinqun Chen
    Chie-Schin Shih
    Kohei Shitara
    Gastric Cancer, 2021, 24 : 1341 - 1341
  • [4] Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Kang, S. Peter
    Mayo, Carlos Alberto
    Ohtsu, Atsushi
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
    Shitara, K.
    Ozguroglu, M.
    Bang, Y. J.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M. H.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Gokkurt, E.
    Mansoor, W.
    McDermott, R.
    Schacham-Shmueli, E.
    Chen, X.
    Kang, S. P.
    Mayo, C.
    Ohtsu, A.
    Fuchs, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Lowery, M.
    Wyrwicz, L.
    Oh, D-Y.
    Shiu, K. K.
    Weber, P. Yanez
    Bai, Y.
    Lee, J.
    Rivera, F.
    Alves, G.
    Garrido, M.
    Fernandez, M. Gonzalez
    Li, J.
    Cil, T.
    Cruz, F.
    Qin, S.
    Yin, L.
    Valderrama, A.
    Bordia, S.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
  • [8] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Yoon, H.
    Fuchs, C.
    Ozguroglu, M.
    Bang, Y.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Van Cutsem, E.
    Elme, A.
    Thuss-Patience, P.
    Chau, I.
    Ohtsu, A.
    Wang, A.
    Bhagia, P.
    Lin, J.
    Shih, C.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S236 - S236
  • [10] Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Van Cutsem, E.
    Valderrama, A.
    Bang, Y-J.
    Fuchs, C.
    Shitara, K.
    Janjigian, Y. Y.
    Qin, S.
    Larson, T.
    Shankaran, V.
    Stein, S.
    Norquist, J. M.
    Kher, U.
    Shah, S.
    Alsina, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 879 - 879
12345